Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-11058639-B2
Application number	US-202016834155-A
Country	US
Kind code	B2
Filing date	Mar 30, 2020
Priority date	Oct 3, 2017
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

First claim

The invention claimed is:

1. A method of treating cancer in a subject, the method comprising:
(a) administering a first composition comprising antineoplastic particles directly into a solid tumor of the subject by intratumoral injection, and
(b) systemically administering a second composition comprising an immunotherapeutic agent to the subject,
thereby treating the cancer, wherein the antineoplastic particles have a mean particle size (number) of from 0.1 microns to 5 microns, wherein steps (a) and (b) can be conducted in any order or at the same time, wherein the antineoplastic particles comprise taxane particles, wherein the taxane particles comprise at least 95% of the taxane, wherein the taxane particles have a specific surface area (SSA) of at least 18 m 2 /g; wherein the taxane particles comprise paclitaxel particles, docetaxel particles, cabazitaxel particles, or combinations thereof; and wherein the immunotherapeutic agent is ipilimumab or atezolizumab.

2. The method of claim 1 , wherein the solid tumor is a benign tumor, and wherein the subject has cancer elsewhere in the body.

3. The method of claim 1 , wherein the solid tumor is a malignant tumor.

4. The method of claim 3 , wherein the malignant tumor comprises a sarcoma, a carcinoma, a lymphoma, a breast tumor, a prostate tumor, a head and neck tumor, a glioblastoma, a bladder tumor, a pancreatic tumor, a liver tumor, an ovarian tumor, a colorectal tumor, a skin tumor, a cutaneous metastasis, a lymphoid, and/or a gastrointestinal tumor.

5. The method of claim 3 , wherein the subject has cancer in other areas of the body.

6. The method of claim 1 , wherein the taxane particles have a mean particle size (number) of from 0.1 microns to 1.5 microns.

7. The method of claim 1 , wherein the taxane particles are paclitaxel particles.

8. The method of claim 7 , wherein the paclitaxel particles have a bulk density (not-tapped) of 0.05 g/cm 3 to 0.15 g/cm 3 .

9. The method of claim 1 , wherein the taxane particles are docetaxel particles.

10. The method of claim 9 , wherein the docetaxel particles have a bulk density (not-tapped) of 0.05 g/cm 3 to 0.15 g/cm 3 .

11. The method of claim 1 , wherein the first composition further comprises a liquid carrier, and wherein the antineoplastic particles are dispersed in the carrier.

12. The method of claim 11 , wherein the liquid carrier is an aqueous carrier.

13. The method of claim 12 , wherein the aqueous carrier comprises 0.9% saline solution.

14. The method of claim 12 , wherein the aqueous carrier comprises a surfactant.

15. The method of claim 14 , wherein the surfactant is a polysorbate.

16. The method of claim 15 , wherein the polysorbate is polysorbate 80, and wherein the polysorbate 80 is present in the aqueous carrier at a concentration of between about 0.01% v/v and about 1% v/v.

17. The method of claim 1 , wherein the concentration of the taxane particles in the first composition is between about 1 mg/ml and about 40 mg/ml, or between about 6 mg/mL and about 20 mg/mL.

18. The method of claim 1 , wherein the composition does not contain albumin.

19. The method of claim 1 , wherein the second composition comprises a pharmaceutically acceptable carrier.

20. The method of claim 1 , wherein the systemic administration is intravenous (IV) injection or oral delivery.

21. The method of claim 1 , wherein the immunotherapeutic agent is ipilimumab.

22. The method of claim 1 , wherein the immunotherapeutic agent is atezolizumab.

23. The method of claim 3 , wherein the malignant tumor comprises a breast tumor.

24. The method of claim 23 , wherein the taxane particles are docetaxel particles.

Assignees

• Crititech Inc

Inventors

• Dizerega Gere S
• Baltezor Michael
• Campbell Sam
• Decedue Charles J
• Mcclorey Matthew

Classifications

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K47/24

  containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/06

  Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite · CPC title

• A61K9/1617

  Organic compounds, e.g. phospholipids, fats · CPC title